Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapy
Immune check point inhibitors have demonstrated efficacy in squamous cell carcinoma of the head and neck (SCCHN) in cases of recurrence or in a metastatic setting after platinum failure [1]. In many tumors, anti PD1 or anti PDL 1 have increased median overall survival (OS) but have not demonstrated greater median progression free survival (PFS) [1 –3]. Recent data has suggested that chemotherapy in post-nivolumab treatment may induce better objective responses than historical data did [4].
Source: Oral Oncology - Category: Cancer & Oncology Authors: Amaury Daste, Erwan De-Mones, Val érie Cochin, Charles Dupin, Laurence Digue, Alain Ravaud, Charlotte Domblides Tags: Letter to the editor Source Type: research
More News: Cancer & Oncology | Carcinoma | Chemotherapy | History of Medicine | Oral Cancer | Skin Cancer | Squamous Cell Carcinoma